Science Corp Reports 36-Month PRIMA BCI Data in Geographic Atrophy

Science Corp. has announced 36-month results from its PRIMA brain-computer interface clinical trial, reporting durable vision restoration in blind patients with geographic atrophy, the advanced form of dry age-related macular degeneration.

The announcement, distributed via Morningstar, marks one of the longest reported follow-up windows for a vision-restoration BCI in this patient population. Three years of sustained function in an implanted intracranial device is the central claim, and it directly addresses the durability question that reading-room clinicians and retinal specialists ask first of any cortical prosthesis.

What the trial covers?

The PRIMA system is designed for patients who have lost central vision to geographic atrophy. In this late-stage disease, photoreceptors in the macula degenerate, but the inner retinal layers and the visual cortex remain largely intact — the premise underlying a prosthetic that bypasses the damaged retina and stimulates the visual pathway directly.

The trial population consists of blind patients, meaning the reported outcomes concern restoration of functional vision rather than augmentation of residual sight. Science Corp. describes the results as showing vision restoration that persisted over the full 36-month observation period.

Why 36 months matters?

Long-term stability is the decisive variable for intracranial visual prostheses. Electrode arrays placed on or beneath the cortical surface face encapsulation, signal degradation, and device failure over time. A sponsor reporting durable performance at three years is claiming that the implant continued to deliver usable visual percepts without loss of efficacy across that window.

For clinical neurophysiology teams, the relevant practical point is straightforward: a cortical visual prosthesis maintaining function at 36 months would require long-term monitoring protocols, similar in spirit to those used for other implanted neurostimulation systems, should the technology reach broader clinical use.

What remains to be seen?

The announcement does not, in the material distributed so far, detail the full quantitative endpoints — letter-recognition scores, orientation and mobility testing, or visual acuity equivalents — that would let clinicians judge the magnitude of restoration. Those details will matter when peer-reviewed publication or regulatory submission follows.

The PRIMA platform originates from research lineage in subretinal and cortical photovoltaic implants, and Science Corp. has positioned it within its broader neurotechnology pipeline. The company has not stated in this release whether the data will support a regulatory filing or an expansion of the trial cohort.

Investors and clinicians alike will now watch for the full dataset: cohort size, safety events across the three years, and standardized vision outcomes. If the 36-month durability holds up under peer review, PRIMA would strengthen the case for cortical visual prostheses as a viable monitoring-and-rehabilitation pathway in end-stage macular degeneration.